Novel opioid antagonists for opioid-induced bowel dysfunction (Q34191604)

31 July 2017

1 reference

title

Novel opioid antagonists for opioid-induced bowel dysfunction (English)

1 reference

31 July 2017

0 references

Laura Diego

1

1 reference

31 July 2017

Rabia Atayee

2

1 reference

31 July 2017

Pieter Helmons

3

1 reference

31 July 2017

Grace Hsiao

4

1 reference

31 July 2017

Charles F von Gunten

5

1 reference

31 July 2017

language of work or name

English

0 references

publication date

12 June 2011

1 reference

Expert Opinion on Investigational Drugs

31 July 2017

1 reference

31 July 2017

20

1 reference

31 July 2017

8

1 reference

31 July 2017

1047-1056

1 reference

Incidence, prevalence, and management of opioid bowel dysfunction

31 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

Development of peripheral opioid antagonists' new insights into opioid effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

Opioid antagonists for prevention and treatment of opioid-induced gastrointestinal effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

Opioid-induced bowel dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

Opioid receptors in the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

Management of opioid-induced gastrointestinal effects in patients receiving palliative care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

Management of constipation in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

Low-dose oral naloxone reverses opioid-induced constipation and analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

Oral naloxone in opioid-associated constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

Opioid side effects--mechanism-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

Methylnaltrexone for opioid-induced constipation in advanced illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

Pathogenesis and clinical and economic consequences of postoperative ileus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

Methylnaltrexone: a novel approach for the management of opioid-induced constipation in patients with advanced illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

Alvimopan∗∗Alvimopan is the official USAN name adopted as of press time. (ADL 8-2698) Is a Novel Peripheral Opioid Antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.592830

10.1517/13543784.2011.592830

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference